Objective To determine the efficacy and safety of Wuzhi capsules combined with tacrolimus for patients undergoing kidney transplantation,and to provide reference for the safe,rational,and effective use of combined immunosuppression therapy.Methods Patients who underwent allogeneic kidney transplantation at Xiangya Hospital of Central South University from January 2020 to February 2021 were collected to determine the effect of coadministration of Wuzhi capsules on the concentration of tacrolimus and incidence of common complications after kidney transplantation and systemic immune inflammation index,and to analyze the efficacy and safety of Wuzhi capsules combined with tacrolimus for renal transplantation patients.Results Totally 87 patients were included.Totally 31 patients(35.63％)were regularly administerted Wuzhi capsules after the transplantation.The trough plasma concentration of tacrolimus was increased,while the daily dose was significantly lower than before(P＜0.001).Hemoglobin was(105.06±15.93)g·L-1 in the Wuzhi capsule group 1 month after the transplantation,which is much lower than that in the tacrolimus group(114.58±17.71)g·L-1(P=0.015).Hemoglobin in the Wuzhi capsules group gradually increased within 3 months after the transplantation until the variance between the two groups finally vanished.The systemic immune inflammation index in the Wuzhi capsule group did not change as compared to that in the tacrolimus group within 1 month after the transplantation,and even reduced significantly 3 months postoperatively(P=0.006).Conclusion Combination of Wuzhi capsules with tacrolimus significantly increases the blood concentration of tacrolimus in kidney transplantation patients and reduces the daily dose of the drug.However,the effect of Wuzhi capsules on the systemic immune-inflammation needs further verification.
关键词
五酯胶囊/他克莫司/肾移植/安全性/全身免疫炎症指数
Key words
Wuzhi capsule/tacrolimus/kidney transplantation/safety/systemic immune inflamma-tion index
维普
万方数据